

VPA10996/245/001

Paracox-8, suspension for oral suspension for chickens

Variation	Summary	Date
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	17/02/26
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	22/12/25
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	22/08/24
Vet - F.II.e.2 z)	VRA-S - Vet - F.II.e.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.2 z) Quality Changes - Container closure system - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	24/10/23
Vet - A1 b)	VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administratvie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.	06/10/23
Vet - F.II.d.1 a)	VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product -Control of finished product - Change in the specification parameters and/or limits of the finished product -	17/06/22

	Change outside the approved specifications limits range	
--	---	--